Building Competency in Diabetes Education THE ESSENTIALS

TREATMENT MODALITIES: PHARMACOLOGICAL THERAPIES | 6-32

(insulin glargine 60 units / lixisenatide 20 mcg/day)

Dose that has demonstrated cardiorenal benefits: • While CV safety has been confirmed for all GLP-1 RA, there is no evidence of CV benefit for lixisenatide

Caution •

Dulaglutide (Trulicity ® ) Long-acting GLP-1 Analogue with 90% sequence homology (resemblance) to human GLP-1. • TDD: 0.75 mg-: 1.5 mg • Frequency: Once weekly • Taken same day of the week at any time. • Missed dose: Taken if >72 hours until next scheduled dose. Dosing schedule • Initiate at 0.75 mg sc once weekly. • Titrate to 1.5 mg sc for added BG control. Dose that has demonstrated cardiorenal benefits: • dulaglutide 1.5mg sc QD

If eGFR <15 mL/min/1.73m 2 Each prefilled pen will deliver:

● 0.75 mg/0.5 mL (1 box = 4 pens) ● 1.5 mg/0.5 mL (1 box = 4 pens) • self-retracting needle included in auto-injector pen.